Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Cutaneous Leishmaniasis Diagnosed by Press Imprint Smear

By Labmedica International staff writers
Posted on 28 Aug 2014
Print article
Image: Leishmania amastigotes from a smear of a patient with cutaneous leishmaniasis (Photo courtesy of University of California, Los Angeles).
Image: Leishmania amastigotes from a smear of a patient with cutaneous leishmaniasis (Photo courtesy of University of California, Los Angeles).
The diagnostic method of choice for cutaneous leishmaniasis historically has been microscopic demonstration of the parasite and isolation of the protozoa in culture and detection of parasite DNA by molecular diagnostic methods.

However most cases of cutaneous leishmaniasis occur in areas without good health infrastructure where diagnostic laboratory facilities are limited, therefore a rapid, sensitive, and inexpensive test for the diagnosis of the disease is needed for use in rural, resource-limited, endemic settings.

Scientists at the Federal University of Ceará (Fortaleza, Brazil) collected skin biopsy samples from 75 patients with a clinical diagnosis of cutaneous leishmaniasis, from September 2011 to August 2013. Two biopsy samples were taken from the borders of ulcers (lesions) using a 3-mm disposable punch. One biopsy specimen was fixed in 10% formalin and processed for histopathology and the other specimen was used for a Press-Imprint-Smear.

For the imprint, the biopsy sample was put on a glass slide, and another glass slide was used to cover the tissue fragment sandwiched in between. On a firm surface, the tissue fragment between both glass slides was squeezed or squashed. Pressure on the middle of the slides was made, and therefore, the juice and tissue cells were spread on both slides surfaces that were in contact with the sample. Smears were air dried, fixed in methanol, stained with Giemsa, and examined microscopically using a 100 × oil immersion lens.

In 69 (92%) patients, the diagnosis of cutaneous leishmaniasis was confirmed by the identification of amastigotes by one or both methods. In 64 (85.3%) patients, amastigotes were detected by Press-Imprint-Smear. In 33 (44%) patients, amastigotes were detected by histopathology, and in 28 (37.3%) patients, amastigotes were detected by both methods. In 36 (48%) patients, parasites were seen only by Press-Imprint-Smear, and in five (6.7%) patients, parasites were seen only by histopathology. Leishmania (Viannia) braziliensis was the only species in this area.

The authors concluded that the Press-Imprint-Smear method was quicker that the histological method as it only took about an hour and had a much higher sensitivity of 85.3% compared with histology at 44%. Considering its sensitivity, low cost, and simplicity, Press-Imprint-Smear is a valuable tool for diagnosing cutaneous leishmaniasis and potentially, other infectious diseases at the point of care in rural or resource-limited endemic regions. The study was published on August 11, 2014, in the American Journal of Tropical Medicine and Hygiene.

Related Links:

Federal University of Ceará



Print article

Channels

Genetic Tests

view channel

Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis

Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases. MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression... Read more

Lab Tech.

view channel

Method Preserves Microfluidic Devices for HIV Monitoring in Developing Countries

Microfluidic devices with immunochemistry have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.